U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugsnews2024-04-15T19:47:14+00:00April 15th, 2024|The New York Times|
How a Drug Company Made $114 Billion by Gaming the U.S. Patent Systemnews2023-01-28T17:39:16+00:00January 28th, 2023|The New York Times|
Prosecute Trump, Despite the Risks?news2022-09-01T20:05:08+00:00September 1st, 2022|The New York Times|
Covid Vaccine and Fisheries Deals Close a ‘Roller Coaster’ W.T.O. Meetingnews2022-06-17T18:44:59+00:00June 17th, 2022|The New York Times|
Omicron Is Here. Will We Use Our New Covid Drugs Wisely?news2021-12-01T23:11:37+00:00December 1st, 2021|The New York Times|
South African Company Nears License to Sell J. & J. Covid Shot Across Africanews2021-11-30T21:07:51+00:00November 30th, 2021|The New York Times|
Here’s Why Developing Countries Can Make mRNA Covid Vaccinesnews2021-10-23T01:56:09+00:00October 23rd, 2021|The New York Times|
Pressure Grows on U.S. Companies to Share Covid Vaccine Technologynews2021-09-22T19:23:27+00:00September 22nd, 2021|The New York Times|
New video: See how strong IP protections lead to stronger treatments for patientsnews2020-11-09T15:00:00+00:00November 9th, 2020|The Catalyst|
